

Hearing held on 4/15/2025. (RE: related document(s) [787] Emergency Motion to enforce EIT Pharma, Inc., formerly known as Eiger InnoTherapeutics, Inc.'s Emergency Motion to Confirm Terms of Lonafarnib/Lambda Sale Order (related document(s): [558] Order on motion to sell) Filed by Interested Party EIT Pharma, Inc., formerly known as Eiger InnoTherapeutics, Inc.) (Appearances: H. Ray, III, J. Morris, J. Dickenson, R. Trechter, and M. Stromberg for Senynl; W. Martin, R. Parisi, and M. Venus for Liquidating Trustee; J. Brookner and E. Shanks for EIT; C. Carson for Progeria Foundation. Nonevidentiary hearing (turned into status conference). After hearing statements of counsel, court determined this contested matter will be tried jointly with Sentynl Motions to Enforce Zokinvy Sale Order and Request for Allowance of an Administrative Expense claim. DE #4 700 & amx 770). Joint Scheduling Order to be submitted \Edmond Michael\



2480040250416000000000007